Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares were up 4.4% on Monday . The company traded as high as $7.42 and last traded at $7.42, with a volume of 81,286 shares. The stock had previously closed at $7.11.

A number of research analysts recently weighed in on KPTI shares. Robert W. Baird started coverage on Karyopharm Therapeutics in a report on Monday, June 27th. They set an “outperform” rating and a $16.00 price objective on the stock. Jefferies Group reaffirmed a “hold” rating and set a $10.00 price objective (down previously from $14.00) on shares of Karyopharm Therapeutics in a report on Tuesday, March 15th. Canaccord Genuity reaffirmed a “buy” rating and set a $20.00 price objective on shares of Karyopharm Therapeutics in a report on Tuesday, March 15th. Wedbush reaffirmed an “outperform” rating and set a $14.00 price objective on shares of Karyopharm Therapeutics in a report on Friday, June 10th. Finally, Zacks Investment Research lowered Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the stock. Karyopharm Therapeutics currently has an average rating of “Buy” and an average target price of $19.50.

The company’s market cap is $272.94 million. The stock’s 50 day moving average is $8.19 and its 200 day moving average is $8.14.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Monday, May 9th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.74) by $0.01. Analysts anticipate that Karyopharm Therapeutics Inc. will post ($3.09) EPS for the current fiscal year.

In related news, major shareholder Ltd Chione sold 18,824 shares of the firm’s stock in a transaction that occurred on Thursday, June 23rd. The stock was sold at an average price of $8.03, for a total value of $151,156.72. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

A hedge fund recently raised its stake in Karyopharm Therapeutics stock. Wells Fargo & Company MN raised its stake in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 1,133.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 134,886 shares of the company’s stock after buying an additional 123,951 shares during the period. Wells Fargo & Company MN owned 0.38% of Karyopharm Therapeutics worth $1,787,000 at the end of the most recent quarter.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other diseases. The Company is developing small molecule Selective Inhibitor of Nuclear Export (SINE), compounds that inhibits the nuclear export protein XPO1.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.